Medical/Pharmaceuticals
Himalaya Therapeutics Announces Interim Phase 2 Results for Mecbotamab vedotin (HTBA3011)
* Preliminary observations in Non-Small Cell Lung Cancer ("NSCLC") support advancing to the registrational stage of the trial; anticipate full interim data set in 4Q'22 * Undifferentiated Pleomorphic Sarcoma ("UPS") and osteosarcoma will advance to Phase 2, part 2 enrollment, which is anticip...
2022-09-12 23:32
1805
SeekIn Receives CE Mark Approval for OncoSeek® Multi-Cancer Detection Test
This Blood-based Multi-Cancer Early Detection Test Combines Protein Tumor Markers And Artificial Intelligence SHENZHEN, China, Sept. 12, 2022 /PRNewswire/ -- SeekIn Inc, a leader in blood-based cancer early detection and monitoring technology, today announced CE (Conformité Européenne) Mark appr...
2022-09-12 21:37
1224
Brain Navi Biotechnology Announced Partnership with Distributor, Medtreq Medical Equipment, to enter the Middle East and Egypt with NaoTrac Neurosurgical Robot
HSINCHU, Sept. 12, 2022 /PRNewswire/ -- Brain Navi, the leading surgical robot manufacture inTaiwan, announced a strategic partnership with distributor, Medtreq Medical Equipment, to expand the distribution of the Surgical Navigation Robot, NaoTrac, throughout the region of GCC region,Jordan, Egy...
2022-09-12 08:31
2196
I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022
* Lemzoparlimab combined with AZA showed encouraging clinical response in higher-risk MDS patients * For patients received initial dose over 3 months, the ORR is 80.6% and for patients received initial dose over 6 months the ORR is 86.7%, CR rate 40% * Lemzoparlimab does not require priming ...
2022-09-10 21:00
1752
First patient enrolled in Erectile Dysfunction prospective randomized study with SELUTION SLR
GENEVA, Switzerland, Sept. 10, 2022 /PRNewswire/ -- An 82-year-old Taiwanese
man has become the first patient to be enrolled in the initial Erectile
Dysfunction (ED) randomized clinical trial (RCT) involving SELUTION SLR™,
MedAlliance's novel sirolimus-eluting balloon.
2022-09-10 06:00
2571
Redbud raises $10M in series A round as CRO focusing on science-driven clinical development
SHANGHAI, Sept. 9, 2022 /PRNewswire/ -- Redbud Medicine, the Delaware -headquartered contract research organization (CRO) announced on Monday following the completion of a series A round fundraising in which MING Bioventures Capital, Delian Capital and the existing Angel round investor Hongfeng C...
2022-09-10 05:13
1738
ESMO 2022 - Great oaks grow from small acorns: oncology is committed to doing its part for sustainability
PARIS, Sept. 10, 2022 /PRNewswire/ -- At ESMO 2022, 9-13 September, Paris, France, the premier cancer congress in Europe, which has gathered 28k participants from 167 countries, many discussions will be around sustainability, prevention and novel approaches which could soon become a reality in t...
2022-09-10 04:46
2126
Prenetics Announces Second Quarter 2022 Financial Results and Raises Full Year Adjusted EBITDA Outlook
* Revenue of US$51.7 million in the second quarter of 2022 * Loss from operations of US$(17.9) million and adjusted EBITDA[1] of US$6.5 million in the same period * Raises full year adjusted EBITDA guidance to the range of US$35 million to US$45 million, with corresponding full year revenue ...
2022-09-09 23:17
5689
WuXi STA Opens a New Sterile Lipid Nanoparticle Formulation Facility to Enhance Global CRDMO Services for Customers
SHANGHAI, Sept. 9, 2022 /PRNewswire/ -- WuXi STA, a subsidiary of WuXi AppTec, today announced the opening of a new sterile lipid nanoparticle (LNP) formulation development and manufacturing facility at its Wuxi city campus. Created in response to the increasing demand for complex injection dosag...
2022-09-09 20:00
1497
111 Inc. Receives Unsolicited Preliminary Non-Binding Proposal to Acquire the Company
SHANGHAI, Sept. 9, 2022 /PRNewswire/ -- 111 Inc. ( "111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company inChina, today announced that its Board of Directors (the "Board") has received an unsolicited preliminary non-binding proposal letter (the "Proposal") dated...
2022-09-09 17:53
1336
Antengene to Present at Upcoming Industry Conferences
SHANGHAI and HONG KONG, Sept. 9, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hem...
2022-09-09 14:43
1066
MGI Celebrates Grand Opening of Its New State-of-the-Art Demo Lab in Japan
TOKYO, Sept. 9, 2022 /PRNewswire/ -- MGI Tech Co., Ltd. (MGI), a global life science leader and innovator, announced today on its first day of IPO inChina the grand opening of a new demonstration laboratory inTokyo, Japan, enhancing Japanese customers' experience. MGI has been expanding the oper...
2022-09-09 09:00
2302
KAZIA TO PRESENT FINAL DATA FROM PAXALISIB PHASE II STUDY IN GLIOBLASTOMA AT ESMO
SYDNEY, Sept. 9, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, today announced that final data from its phase II study of paxalisib in patients with newly diagnosed glioblastoma will be the subject of an oral presentation a...
2022-09-09 06:00
2319
New Study in JNCCN Suggests Way to Predict Outcomes with High Accuracy Prior to Surgery for Pancreatic Cancer Patients
According to Mayo Clinic Comprehensive Cancer Center researchers, metabolic imaging (FDG-PET) in combination with traditional treatment response assessment methods can provide clinicians with critical information they need to guide therapy for pancreatic cancer patients. Increasingly impactful n...
2022-09-09 05:40
1576
YishengBio Received Approvals From Philippines and UAE For Phase 2 / 3 Clinical Trials of PIKA Recombinant COVID-19 vaccine
BEIJING, Sept. 8, 2022 /PRNewswire/ -- YishengBio Co., Ltd., ("YishengBio"), a biopharmaceutical company dedicated to discovery, development, manufacturing and commercialization of new generations of vaccines and therapeutic biologics, announced that the Company received the approvals from the re...
2022-09-08 21:33
2377
Nutromics raises US$14 million for its ground-breaking wearable diagnostic platform
MELBOURNE, Australia and SAN DIEGO, Sept. 8, 2022 /PRNewswire/ -- Global MedTech start-up Nutromics has raised an additional US$14 million for its wearable diagnostic platform. This transformative funding is key to Nutromics' continued expansion acrossAustralia and the United States. Strategic in...
2022-09-08 20:54
2213
Pulnovo Medical Concludes Successfully the First Steering Committee Meeting
SHANGHAI, Sept. 8, 2022 /PRNewswire/ -- Pulnovo Medical Limited, a globally
recognized OTM innovative platform, today announced that it has successfully
concluded the first Steering Committee meeting for PADN Global Clinical Trial.
2022-09-08 20:30
1237
Hummingbird Bioscience Announces Trial in Progress Poster Presentation at the European Society for Medical Oncology Congress 2022
* HMBD-001 is a proprietary anti-HER3 antibody in an ongoing Phase 1 trial targeting multiple solid tumors * HMBD-001 has the potential to fully block both ligand-dependent and -independent HER3 signaling SINGAPORE, Sept. 8, 2022 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision...
2022-09-08 20:00
1754
ONE DRUG FOR ONE BUG: DEBIOPHARM TO DISCUSS THE POTENTIAL OF PATHOGEN-SPECIFIC ANTIBIOTICS AT THE 2022 WORLD AMR CONGRESS
* International health authorities, such as the WHO and the CDC are warning of the emerging danger of bacterial infections resistant to current antibiotics * The 2022 World Anti-Microbial Resistance (AMR) Congress in the greater Washington D.C. area is serving as a forum to openly address the ...
2022-09-08 16:41
1461
NeuroXess Attends WAIC with its First Medical-Grade BCI Product Pipeline
SHANGHAI, Sept. 8, 2022 /PRNewswire/ -- The Brain Sciences Theme Forum of 2022 World Artificial Intelligence Conference (WAIC) was held at Shanghai World Exhibition and Convention Center onSeptember 2. NeuroXess, a China-based high-tech life science company focusing on flexible electrode BCI (br...
2022-09-08 16:19
1434
Week's Top Stories
Most Reposted
Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
[Picked up by 318 media titles]
2024-05-15 12:00
Home to half of the world's top 10 trending tourism destinations, Asia Pacific is making a comeback: Mastercard Economics Institute on travel in 2024
[Picked up by 301 media titles]
2024-05-16 15:00
US-BASED PANDUIT ELEVATES MANUFACTURING LANDSCAPE WITH NEW STATE-OF-THE-ART PLANT IN JOHOR BAHRU, MALAYSIA
[Picked up by 274 media titles]
2024-05-16 09:39
Central Embassy, celebrates its 10th anniversary with a world-class immersive presentation--the first of its kind in Thailand--by renowned artist Daniel Arsham
[Picked up by 272 media titles]
2024-05-10 15:20
Where does China's production capacity come from?
[Picked up by 258 media titles]
2024-05-10 12:01Most Read
Huawei Launching the All-Scenario Smart Telecom Power Solutions
2024-05-11 17:52
8601
Central Embassy, celebrates its 10th anniversary with a world-class immersive presentation--the first of its kind in Thailand--by renowned artist Daniel Arsham
2024-05-10 15:20
7969
Where does China's production capacity come from?
2024-05-10 12:01
7807
China Jo-Jo Drugstores Announces $2.74 Million Registered Direct Offering
2024-05-10 21:20
4977